首页 | 官方网站   微博 | 高级检索  
     

复方血栓通胶囊对早期糖尿病肾病患者血清炎性指标的影响
引用本文:张桢.复方血栓通胶囊对早期糖尿病肾病患者血清炎性指标的影响[J].中国医药指南,2013(34):13-14.
作者姓名:张桢
作者单位:河南省商丘市第一人民医院内分泌科,河南商丘476000
摘    要:目的探讨复方血栓通胶囊对早期糖尿病肾病患者血清CRP、TNF-α、IL-6的影响。方法将血压正常的90例早期糖尿病肾病患者随机分为对照组和治疗组。对照组予以控制血糖、糖尿病教育等常规治疗;治疗纽在常规治疗的基础上加用复方血栓通胶囊3粒,每日3次,均治疗12周。观察治疗前后二组患者血清CRP、TNF-α、IL-6及尿微量白蛋白的变化。结果治疗12周后,治疗组与治疗前相比尿微量白蛋白及血清CRP、TNF-α、IL-6均较前明显降低;且明显优于对照组。结论复方血栓通胶囊能明显降低早期糖尿病肾病患者尿微量白蛋白及血清CRP、TNF-α、IL-6水平,对早期糖尿病肾病具有治疗作用。

关 键 词:复方血栓通胶囊  早期糖尿病肾病  炎性指标

Effect of Fufang Xueshuantong Capsule on Serum Inflammatory Indicators of Early Diabetic Nephropathy Patients
ZHANG Zhen.Effect of Fufang Xueshuantong Capsule on Serum Inflammatory Indicators of Early Diabetic Nephropathy Patients[J].Guide of China Medicine,2013(34):13-14.
Authors:ZHANG Zhen
Affiliation:ZHANG Zhen (Department of Endocrinology, The First People's Hospital of Shangqiu, Shangqiu 476000, China)
Abstract:Abstract]Objective To observe the influence of Fufang Xueshuantong capsule on serum CRP, TNF-α. IL-6 of Early Diabetic Nephropathy Patients. Methods Ninety patients who Blood pressure is in the normal range were divided into control group and treatment group,All of them were given Control blood glucose,diabetic education Conventional treatment and so on. While those in treatment group,besides of treatment as control group,were given Fufang Xueshuantong capsule,All treatment course were 12 weeks.Then the urinary microalbumin and the serum CRP. TNF-α. IL-6 were measured before and after treatment.Results After 12 weeks treatment,the level of UAER,CRP TNF-α,IL-6 of the two groups were lower than those before,but the treatment group decreased significantly. Conclusion Fufang Xueshuantong capsule can decrease the urinary microalbumin and the serum CRP. TNF-α, IL-6 of early diabetic nephropathy patients,and has therapeutical effect to them.
Keywords:Fufang Xueshuantong capsule  Early stage of Diabetic Nephropathy  Serum inflammatory makers
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司    京ICP备09084417号-23

京公网安备 11010802026262号